Half Year Results 

Indivior upgrades full-year forecasts

Indivior upgrades full-year forecasts

Management at Indivior (INDV) has raised its full-year guidance after a particularly strong first half, which saw the company's operating margin rise by 7 percentage points to 44 per cent. Indivior, which specialises in medication for opioid addiction, saw improved market growth in the US and fought to maintain market share for its Suboxone Film treatment. Management now anticipates net revenue to be in the range of $1.09bn to $1.12bn, up from its original forecast of $1.05bn to $1.08bn. The upgraded forecasts, combined with lower legal costs and a possible new drug launch, sent the shares up 5 per cent on the release of the figures.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now